LONDON - Acambis plc was forced to double the number of subjects in a Phase I study of its West Nile vaccine after two adverse events forced suspension of the trial. The expansion, from 60 to 120 subjects, will delay the results until 2005. (BioWorld International)
LONDON - Acambis plc was forced to double the number of subjects in a Phase I study of its West Nile vaccine after two adverse events forced suspension of the trial. The expansion, from 60 to 120 subjects, will delay the results until 2005. (BioWorld International)
LONDON - Microscience Ltd. is looking to raise £40 million (US$71.6 million) in an initial public offering on London's Alternative Investment Market to finance development of five vaccines in clinical trials. The company is expected to have market capitalization of £120 million to £140 million. (BioWorld International)
